B. Riley Predicts Stronger Earnings for Kymera Therapeutics

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Stock analysts at B. Riley increased their FY2025 EPS estimates for Kymera Therapeutics in a research note issued to investors on Wednesday, November 5th. B. Riley analyst M. Mamtani now forecasts that the company will post earnings of ($3.39) per share for the year, up from their prior forecast of ($3.82). B. Riley has a “Buy” rating and a $80.00 price objective on the stock. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share. B. Riley also issued estimates for Kymera Therapeutics’ Q4 2025 earnings at ($0.91) EPS, FY2026 earnings at ($4.01) EPS, FY2027 earnings at ($4.51) EPS and FY2028 earnings at ($4.04) EPS.

KYMR has been the topic of a number of other research reports. Wells Fargo & Company lifted their target price on Kymera Therapeutics from $53.00 to $69.00 and gave the company an “overweight” rating in a research report on Wednesday. Oppenheimer restated an “outperform” rating and issued a $67.00 price objective on shares of Kymera Therapeutics in a report on Tuesday. Mizuho began coverage on shares of Kymera Therapeutics in a research note on Tuesday, October 21st. They set an “outperform” rating and a $81.00 target price for the company. Truist Financial lifted their price target on shares of Kymera Therapeutics from $53.00 to $68.00 and gave the company a “buy” rating in a research report on Tuesday, September 30th. Finally, Wall Street Zen lowered shares of Kymera Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 16th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $69.75.

Kymera Therapeutics Stock Performance

KYMR opened at $61.00 on Friday. The stock has a market capitalization of $4.39 billion, a PE ratio of -16.99 and a beta of 2.32. Kymera Therapeutics has a one year low of $19.44 and a one year high of $63.96. The business’s 50 day moving average price is $53.84 and its 200 day moving average price is $44.88.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). The firm had revenue of $2.76 million for the quarter, compared to analyst estimates of $23.15 million. Kymera Therapeutics had a negative return on equity of 32.92% and a negative net margin of 674.81%.

Institutional Investors Weigh In On Kymera Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. raised its holdings in Kymera Therapeutics by 9.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,764 shares of the company’s stock worth $156,000 after purchasing an additional 248 shares during the last quarter. Farther Finance Advisors LLC raised its stake in Kymera Therapeutics by 642.9% in the 2nd quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock valued at $27,000 after purchasing an additional 540 shares during the last quarter. Comerica Bank lifted its holdings in Kymera Therapeutics by 3.6% in the 1st quarter. Comerica Bank now owns 21,374 shares of the company’s stock valued at $585,000 after purchasing an additional 743 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Kymera Therapeutics by 506.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock worth $40,000 after purchasing an additional 770 shares during the last quarter. Finally, Bessemer Group Inc. grew its holdings in shares of Kymera Therapeutics by 652.0% during the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after buying an additional 815 shares in the last quarter.

Insider Activity at Kymera Therapeutics

In other news, Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction that occurred on Monday, October 13th. The stock was sold at an average price of $59.19, for a total transaction of $295,950.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Bruce N. Jacobs sold 79,220 shares of the firm’s stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $50.00, for a total value of $3,961,000.00. Following the completion of the sale, the chief financial officer directly owned 227,409 shares of the company’s stock, valued at approximately $11,370,450. This trade represents a 25.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 206,910 shares of company stock valued at $11,402,648 over the last quarter. 16.01% of the stock is owned by insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.